Cardinal Health INC

Cardinal Health reported strong third quarter fiscal year 2026 results, with revenue increasing 11% to $60.9 billion and non-GAAP diluted EPS rising 35% to $3.17, leading the company to raise its full-year outlook.

Cardinal Health announced the retirement of Board Chair Gregory B. Kenny and the appointment of Patricia A. Hemingway Hall, while reaffirming its fiscal 2026 outlook.

Cardinal Health's Senior Vice President and Chief Accounting Officer, Mary Scherer, has announced her intention to retire in February 2027.

Cardinal Health reported robust second-quarter fiscal year 2026 results with significant revenue and earnings growth, leading to an upward revision of its full-year non-GAAP EPS guidance.

Cardinal Health has raised its fiscal year 2026 non-GAAP diluted earnings per share outlook to at least $10.00, driven by accelerating specialty growth and successful navigation of IRA changes.

Cardinal Health, Inc. announced the results of its 2025 Annual Meeting, where shareholders elected 12 directors, approved executive compensation, and ratified Ernst & Young LLP as auditor.

Cardinal Health reported an 11% increase in revenue for the third quarter of fiscal year 2026, driven by strong performance in its Pharmaceutical and Specialty Solutions segment.

Cardinal Health announced robust financial results for Q2 fiscal year 2026, with significant revenue and earnings growth fueled by strategic acquisitions and strong performance across its segments.

Cardinal Health reports a robust start to fiscal year 2026 with significant revenue and operating earnings growth, driven by strategic acquisitions and strong pharmaceutical sales.

Cardinal Health's Q3 Fiscal 2025 shows a significant increase in GAAP and non-GAAP operating earnings, driven by pharmaceutical segment growth and strategic acquisitions.

Cardinal Health's second quarter fiscal 2025 results show a revenue decrease due to contract expirations, offset by growth in other areas and strategic acquisitions.

Cardinal Health's first quarter fiscal 2025 results show a revenue decrease of 4% due to the expiration of a major contract, though non-GAAP operating earnings increased by 12%.

Cardinal Health reports significant earnings growth in fiscal 2025, driven by strategic acquisitions and specialty pharmaceutical sales, despite a revenue dip from contract expirations.

Cardinal Health's fiscal year 2024 performance showcased robust revenue growth, driven by increased demand in branded and specialty pharmaceuticals, despite the expiration of key contracts and ongoing industry challenges.

Director Patricia Hemingway Hall was granted 381 restricted stock units following her appointment as Chair of the Board.

Cardinal Health's Chief Information Officer, Michelle D. Greene, sold 2,746 common shares for approximately $228.51 per share under a pre-arranged 10b5-1 plan.

Cardinal Health's Chief Human Resources Officer, Valerie Christine Pitteroff, was granted 3,982 restricted share units valued at $213.26 per share.

Cardinal Health's Chief Human Resources Officer, Ola M. Snow, disposed of 320 common shares to cover tax withholding obligations related to restricted share units.

Cardinal Health's Chief Legal/Compliance Officer, Jessica L. Mayer, disposed of 422 common shares to cover tax withholding obligations related to restricted share units.

Deborah Weitzman, CEO of Cardinal Health's PSS Segment, reported the withholding of 551 common shares to cover tax obligations related to restricted share units.

Cardinal Health, Inc. has filed a Definitive Proxy Statement with the SEC.

Cardinal Health achieved double-digit profit growth across all operating segments in fiscal 2025, driven by strategic acquisitions and operational efficiencies, despite a major contract expiration.

Cardinal Health filed a supplement to its proxy statement to include Inline XBRL tagging and clarify the application of its clawback policy following the correction of an accounting error related to revenue recognition in the at-Home Solutions segment.

Cardinal Health has updated its proxy statement to reflect that director Michelle M. Brennan no longer qualifies as an independent director due to her appointment as interim CEO of Masimo Corporation, a company with which Cardinal Health has a significant commercial relationship.

Cardinal Health has filed a definitive proxy statement with the Securities and Exchange Commission.

Cardinal Health's proxy statement emphasizes a strong fiscal 2024 performance driven by strategic progress and shareholder value creation.

Vanguard Capital Management has disclosed a beneficial ownership of 7.49% in Cardinal Health Inc., holding over 17.6 million shares.

Vanguard Portfolio Management has reported beneficial ownership of 5.85% of Cardinal Health Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership stake in Cardinal Health Inc. following an internal realignment that disaggregated reporting to its subsidiaries.

BlackRock Portfolio Management LLC has filed an amended Schedule 13G, reporting a 3.8% beneficial ownership stake in Cardinal Health Inc. as of December 31, 2025.

BlackRock Portfolio Management LLC has reported a 5.0% beneficial ownership stake in Cardinal Health Inc., holding 11,947,456 shares of common stock as of September 30, 2025.

BlackRock Portfolio Management LLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 4.7% of Cardinal Health Inc.'s common stock as of June 30, 2025.